Calidi Biotherapeutics is offering 1,025,640 common shares at $1.17 each, targeting approximately $1.1 million in net proceeds. Investors should note the funds are intended for Working Capital and corporate purposes, while the company says additional financing is needed to sustain operations and raises substantial doubt about going concern.

Key Highlights

  • Calidi Biotherapeutics expects approximately $1.1 million in net proceeds after estimated offering expenses.
  • The securities sale covers 1,025,640 common shares priced at $1.17 each.
  • The company expects 3,685,849 common shares to be outstanding after the offering.

Calidi Biotherapeutics, Inc. (AMEX: CLDI) is a biotechnology company. It is offering 1,025,640 shares of Common Stock at $1.17 per share, with estimated net proceeds of approximately $1.1 million after offering expenses.

$1.17 Share Sale Sets Post-Offering Count

The expected post-offering share count is 3,685,849, including 9,375 non-voting Escalation Shares, compared with a September 16, 2026 base of 2,660,209 shares that also includes 9,375 such shares. Calidi Biotherapeutics says it will direct the proceeds toward working capital and general corporate purposes, including advancing pre-clinical and clinical programs. The company says it will not pay placement-agent fees, Underwriting discounts or commissions for the offering.

Capital Needs Remain a Stated Risk

Recurring operating losses and the need for additional funding raise substantial doubt about its ability to continue as a going concern.